Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: GlobalData
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

LeMaitre Vascular Inc acquires Xenotis

Monday, 18 Aug 2014 10:14am EDT 

LeMaitre Vascular Inc:Acquires Xenotis, the manufacturer and marketer of the Omniflow II biological graft for peripheral bypass and dialysis access, on Aug. 14.Total consideration for 100pct of Xenotis' shares was $7.7 million, consisting of $5.1 million at the closing, $1.4 million due Aug. 13, 2015 and assumed bank debt of $1.2 million. 

Company Quote

-0.04 -0.53%
26 Dec 2014